Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 



eLetters published in the past 60 days:

Read letters published in the last 1, 7, 14, 30, 60, 90 days.
[Complete eLetters Archive]

6 eLetters published for 5 different topic sources.

Articles    Letters
Jump to eLetters for citation
CHEST IMAGING AND PATHOLOGY FOR CLINICIANS:
A 30-Year-Old Man With a History of Polysubstance Abuse and Hepatitis C Presents With Exertional Dyspnea and Patchy Ground-Glass Opacities
Girvin and Vlahos (1 November 2006) [Full text] [PDF]
Jump to eLetter Foreign body granulomatosis should be considered
Yuji Oba   (5 December 2006)
 Read every eLetter to this article

Jump to eLetters for citation
SLEEP MEDICINE:
An Oral Hypnotic Medication Does Not Improve Continuous Positive Airway Pressure Compliance in Men With Obstructive Sleep Apnea
Bradshaw et al. (1 November 2006) [Abstract] [Full text] [PDF]
Jump to eLetter Oral clonidine as a sedative agent to establish children on non-invasive ventialtion
Jayesh M Bhatt, et al.   (6 December 2006)
 Read every eLetter to this article

Jump to eLetters for citation
editorials:
Did Lady Windermere Have Cystic Fibrosis?
Rubin (1 October 2006) [Full text] [PDF]
Jump to eLetter Thank you, Dr. Reich
Bruce K. Rubin   (21 November 2006)
Jump to eLetter Lady Windermere Syndrome
Jerome M Reich   (21 November 2006)
 Read every eLetter to this article

Jump to eLetters for citation
editorials:
Decreased Recognition of the Post-Myocardial Infarction (Dressler) Syndrome in the Postinfarct Setting: Does It Masquerade as "Idiopathic Pericarditis" Following Silent Infarcts?
Spodick (1 November 2004) [Full text] [PDF]
Jump to eLetter post mi pericarditis
neil d kushner md   (23 December 2006)
 Read every eLetter to this article

Jump to eLetters for citation
critical care reviews:
Adult Toxicology in Critical Care: Part I: General Approach to the Intoxicated Patient
Mokhlesi et al. (1 February 2003) [Abstract] [Full text] [PDF]
Jump to eLetter Too early to draw a conclusion for activated charcoal
Yi Li, et al.   (22 November 2006)
 Read every eLetter to this article
CHEST IMAGING AND PATHOLOGY FOR CLINICIANS:
A 30-Year-Old Man With a History of Polysubstance Abuse and Hepatitis C Presents With Exertional Dyspnea and Patchy Ground-Glass Opacities
Girvin and Vlahos (1 November 2006) [Full text] [PDF]
A 30-Year-Old Man With a History of Polysubstance Abuse and Hepatitis C Presents...
Foreign body granulomatosis should be considered
5 December 2006
 Next eLetter Top
Yuji Oba,
Associate Professor of Medicine
University of Missouri-Columbia

Send letter to journal:
Re: Foreign body granulomatosis should be considered

obay{at}health.missouri.edu Yuji Oba

The clinical history and radiographic findings presented by Girvin and Vlahos in Postgraduate Education Corner (1 )are highly suggestive of foreign body granulomatosis. And it should be considered in the differential diagnosis of pulmonary interstitial disease, especially in the setting of intravenous drug abuse. Foreign body material is readily identifiable within the giant cells and is particularly well seen by polarization microscopy.(2)

References 1. Girvin F and Vlahos I. A 30-Year-Old Man With a History of Polysubstance Abuse and Hepatitis C Presents With Exertional Dyspnea and Patchy Ground-Glass Opacities. Chest 2006;130: 1608-1611 2. Hasleton PS. Spencer's Pathology of the Lung. 5th ed. McGraw-Hill 1996;527

SLEEP MEDICINE:
An Oral Hypnotic Medication Does Not Improve Continuous Positive Airway Pressure Compliance in Men With Obstructive Sleep Apnea
Bradshaw et al. (1 November 2006) [Abstract] [Full text] [PDF]
An Oral Hypnotic Medication Does Not Improve Continuous Positive Airway Pressure...
Oral clonidine as a sedative agent to establish children on non-invasive ventialtion
6 December 2006
Previous eLetter Next eLetter Top
Jayesh M Bhatt,
Respiratory Paediatrcian
Nottingham University Hospitals,
Robert Primhak, Anton Mayer. Sheffield Children's Hospital

Send letter to journal:
Re: Oral clonidine as a sedative agent to establish children on non-invasive ventialtion

jayesh.bhatt{at}nuh.nhs.uk Jayesh M Bhatt, et al.

Dear Sir

We read with interest the paper by Bradshaw et al1 regarding the use of an oral hypnotic medication to improve compliance with CPAP therapy in men with obstructive sleep apnea. They found no increase in initial compliance with CPAP after 14 days treatment with a relatively short acting nonbenzodiazepine hypnotic agent. The initiation of any nocturnal non-invasive ventilation (NIV) can be even more challenging in small children and may not be successful on the first attempt, even when the need for such intervention may be pressing 2,3. In such situations we have used clonidine to establish children on non- invasive ventilation. Clonidine, an a2-adrenoceptor agonists is a non-respiratory depressant sedative and has been used as a sedative agent in various settings including ventilated patients in combination with intravenous morphine and lorazepam 4, in patients with burns5. It produces sedation comparable to diazepam and causes less effect on psychomotor function6.

We urgently needed to initiate non-invasive ventilation in two young children with nocturnal respiratory failure. Case 1. A 2 year 7 month old girl with an axonal neuropathy with predominant cervical distribution, diaphragmatic weakness and nocturnal hypoventilation was suffering significant desaturations during sleep. Case 2. A 3 year 2 month old child with a repaired thoracolumbar spina bifida, shunted hydrocephalus, mild developmental delay, right vocal cord palsy had persistent severe sleep disordered breathing with hypoxaemia and a mixed pattern of apnoeas, despite previous surgical decompression of her formanen magnum, tonsillectomy, and medical treatment for gastro- oesophageal reflux. In both cases we were unable to initate NIV despite the involvement of play therapists and parents in acclimatisation. We therefore tried clonidine as a sedating agent to allow initiation. The clonidine was instituted in the following regimen: After a test dose of 1 microgram/kg, the dose was escalated incrementally (1 to 3 to 5 micrograms/kg/dose) every eight hours (maximum dose of 5 micrograms/kg/dose six hourly)

Successful nasal mask ventilation was established within 24 hours in both cases, and by day 5, withdrawal of Clonidine was started in the following manner: Halve dose but keep frequency the same until on 0.25mcg/kg tds then Reduce frequency to twice daily for 1 day then Reduce frequency to once daily for 1 day then stop

Both continued to tolerate NIV after withdrawal of the drug. During the weaning period blood pressure and heart rate were monitored 4 hourly, and patients were observed for development of agitation and sweating. No adverse effects occurred.

In our cases the children were totally intolerant of NIV and yet were safely and successfully established on it with the use of clonidine as a non-respiratory depressant sedative. As far as we know this is the first described use of clonidine as a sedative for establishment of NIV in very young children. Clearly in most cases such an approach will be unnecessary, but in young children who refuse NIV, we suggest that attempts should not be abandoned without a trial of clonidine. We agree with Bradshaw et all that further studies to evaluate the potential roles of hypnotic agents in subpopulations of patients in the need for establishing NIV are needed and suggest that the role of clonidine is worth exploring in a randomised trial setting.

References

1.Bradshaw DA, Ruff GA, Murphy DP. An Oral Hypnotic Medication does not improve continous positive airway pressure compliance in men with obstructive sleep apnea. Chest 2006;130:1369-1376

2.Simonds AK, Ward S, Heather S, Bush A, Muntoni F. Outcome of paediatric domiciliary mask ventilation in neuromuscular and skeletal disease. European Respiratory Journal 2000;16:476-81

3.Massa F, Gonsalez S, Laverty A, Wallis C, Lane R. The use of nasal continuous positive airway pressure to treat obstructive sleep apnoea. Archives of Disease in Childhood 2002;87:438-43

4.Arenas-Lopez S, Riphagen S, Tibby S, Durwald A, Tomlin S, Davies G, Murdoch I. Use of oral clonidine for sedation in ventilated paediatric intensive care patients. Intensive Care Medicine 2004;30:1625-9.

5.Kariya N, Shindoh M, Nishi S, Yukioka H, Asada A. Oral clonidine for sedation and analgesia in a burn patient. J Clin Anesth 1998;10:514-7

6.Jatti K, Batra Y, Bhardwaj N, Malhotra S. Comparison of psychomotor functions and sedation following premedication with oral diazepam and clonidine in children. Int J Clin Pharmacol Ther 1998;36:336-9

editorials:
Did Lady Windermere Have Cystic Fibrosis?
Rubin (1 October 2006) [Full text] [PDF]
Did Lady Windermere Have Cystic Fibrosis?
Thank you, Dr. Reich
21 November 2006
Previous eLetter Next eLetter Top
Bruce K. Rubin,
Physician, scientist, skeptic
Wake Forest University School of Medicine

Send letter to journal:
Re: Thank you, Dr. Reich

brubin{at}wfubmc.edu Bruce K. Rubin

To the editor Dr. Reich appears to have 3 quibbles with two of my editorials. I appreciate the opportunity to address each of these.

[1] Dr. Reich is bothered by an exchange of letters related to an important article regarding chronic cough in children by Marchant and colleagues (1), recently published in Chest with an accompanying editorial (2). It is not clear why he is unhappy with this editorial or how this is related to the relationship of atypical Mycobacteria infection and bronchiectasis to an unrecognized diagnosis of cystic fibrosis (CF). I stand by my decision recommending the publication of the manuscript by Marchant and I am pleased that this manuscript and editorial have generated discussion.

[2] Dr. Reich is also bothered by my recent editorial (3) regarding the informative manuscript by Ziedalski and colleagues (4) where I discuss the meaning of "the Lady Windermere syndrome" (5). Reich gallantly steps to the defense of the besieged Lady Windermere claiming that medical eponyms are no more than tropes. However most medical eponyms are named for the physician who either first described a specific sign or syndrome or more often, the physician whose recognition of this syndrome was broadly popularized. Thus we have Kartagener syndrome (6) rather than Siewert syndrome (7) although the latter's paper was published 29 years before Kartagener's description in 1933. Occasionally an eponym is named for the patient or the family who have the syndrome and in this case, the eponym is written in the possessive. I am even aware of one instance in pulmonary medicine where the patient with the sign and the describing physician are one and the same - that is the Schamroth digital clubbing sign described by Leo Schamroth of South Africa in 1976 (8). However medical eponyms are not tropes. The Pickwickian syndrome was meant as a description of daytime somulance in the fat boy Joe (I suspect that the name "Joe's syndrome" would be too pedestrian), and even Ondine's curse was meant to describe the fatal curse placed on Ondine's lover so that he lost his autonomic physiologic regulation. These literary eponyms have fallen into disuse with the terms "obesity hypoventilation syndrome", and "congential central hypoventilation syndrome" more descriptively taking their place.

Scholars have pointed out that Wilde's Lady Windermere was certainly not an inhibited Victoran woman (9). Her refusal to shake hands with the Lord Darlington could be an attempt to avoid close contact with this cad but more probably just it was just common politelness not to shake his hand when her hands were wet. Dr. Reich could have chosen to name this syndrome after Cecily Cardew from Wilde's, Importance of Being Earnest:

Act 2 Scene 3: Cecily is taking dictation of a marriage proposal from Algernon.

"Oh, don't cough, Ernest.When one is dictating one should speak fluently and not cough. Besides, I don't know how to spell a cough."

However this is irrelevant given my response to Dr. Reich's third protest.

[3] The crux of this matter is that patients who have bronchiectasis –“isolated” or otherwise - and atypical Mycobacteria do not develop this because of an ineffective cough. Furthermore, it is now clear that many of them either have CF or are a CF heterozygote. What is the evidence for this? 1. There are no published data demonstrating that voluntary cough supression leads to disease; much less to middle lobe or lingular infection with aytpical Mycobacteria. 2. Patients with neuromuscular problems and weak cough are clearly at risk for pneumonia (10) but they do not develop bronchiectasis unless they are immunosupressed or have frequent aspiration of oral or gastric contents. When these patients do get bronchiectasis it is almost never due to atypical Mycobacteria. Thus cough supression does not cause this syndrome. 3. Patients with the "middle lobe syndrome" and persistent collapase of the middle lobe or lingula do indeed get bronchiectasis (more than 20% in most series) but this is almost never due to atypical Mycobacteria (11). Thus poor collateral ventilation does not predispose to Mycobacteria. 4. Ziedalski and colleagues have now clear shown that otherwise healthy adults with bronchiectasis that is not diffuse, and with infection by atypical Mycobacteria, frequently have CF or are CF carriers (4).

The implications of this are great. CF is now a fairly controllable diease with most patients living into adulthood with preserved lung function and good quality of life. The earlier CF is recognized and infections treated, the better the outcome. Diagnosis thus has great implications for treatment and for counseling. This is not to say that all otherwise healthy patients with pulmonary infection caused by atypical Mycobacteria and/or mild bronchiectasis have CF; however this diagnosis appears to be considreably more likely than the suggestion that this is due to an ineffective cough.

The principle of lex parsimoniae suggests that entities should not be multiplied beyond necessity (entia non sunt multiplicanda praeter necessitatem). Reduction to a most likley etiology does not identify CF as the sole cause of Lady Windermere syndrome, however reduction which leads to the assumption that this syndrome is caused by ineffective cough is better characterized as reductio ad absurdum.

As a student of medical history, I find it sad to write a eulogy over a literary eponym that has outlived its usefulness. Reich is to be congratulated for directing our attention to the association of atypical Mycobacteria and isolated bronchiectasis. His explanation for this association presented an innovative and testable hypothesis, which has been shown to be incorrect. I invite him to drop his ideology, accept the etiology, and celebrate with me the identification of the most important established cause for this disease association that he brought to our attention nearly 15 years ago.

References

1. Marchant JM, Masters IB, Taylor SM, Cox NC, Seymour GJ, Chang AB. Evaluation and outcome of young children with chronic cough. Chest. 2006;129:1132-41

2. Rubin BK. Pediatricians are not just small internists. Chest. 2006;129:1118-21.

3. Rubin BK. Did Lady Windermere have cystic fibrosis? Chest. 2006;130:937-8.

4. Ziedalski, T, Kao, P, Henig, N, et al Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006;130,995-1002.

5. Reich, JM, Johnson, RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere syndrome. Chest 1992; 101,1605-1609.

6. Siewert AK. Uber einem Fall von Bronchiectasie bei einem Patienten mit Situs inversus viscerum. Berliner klinische Wochenschrift. 1904;41:139–141.

7. Kartagener M. Zur Pathogenese der Bronchiektasien: Bronchiektasien bei Situs viscerum inversus. Beiträge zum Klinik der Tuberkulose, 1933;83: 489-501. 8. Schamroth L. Personal experience. S Afr Med J 1976;50:297-300.

9. Drew EW. Have you read Lady Windermere’s fan by Oscar Wilde? Chest e-letter December 11, 2002. Available at: http://www.chestjournal.org/cgi/eletters/101/6/1605. Accessed August 30, 2006

10. van der Schans CP, Bach JR, Rubin BK. Chest Physical Therapy: Mucus Mobilizing Techniques. in Noninvasive Mechanical Ventilation. Ed. John R. Bach. Hanley & Belfus, Inc. Philadelphia, PA. 2002 pp 259-284.

11. Rubin BK. Respecting the middle lobe syndrome. Pediatr Pulmonol. 2006;41:803-4.

Did Lady Windermere Have Cystic Fibrosis?
Lady Windermere Syndrome
21 November 2006
Previous eLetter Next eLetter Top
Jerome M Reich,
physician
Earl A Chiles Research Institute, Portland, Oregon

Send letter to journal:
Re: Lady Windermere Syndrome

Reichje{at}dnamail.com Jerome M Reich

Word count: 501 Lady Windermere Syndrome

Greater discernment would have circumvented the need for Marchant and Chang to correct misquotations and tabulate seven “clarifications” in response(1) to Dr. Rubin’s editorial and exempted from comment an editorial (2) in which he inferred that the constellation of bronchiectasis and M. avium disease in Lady Windermere Syndrome(3)(LWS) constituted evidence of cystic fibrosis (CF). Bronchiectasis in LWS is isolated to the lingula and middle lobe, typically the most dependent portions. These lobes share distinctive features: dependency in the upright position; lengthy and narrow bronchi; and absence of collateral ventilation. Some cases are associated with a narrow chest or pectus deformity, which compress these lobes. Collectively, these predispose to stasis, increasing the requirement for tussive clearance. CF is a systemic disorder; radiographs demonstrate widespread bronchiectasis, with upper lobe shadowing predominant. (Lower lobes are preferentially affected in bronchiectasis, most likely due to gravitational facilitation of upper lobe clearance. The distinctive shadowing in CF may be due to the gravitational-offsetting- effect of viscid and tenacious secretions in that region where thoracic inflexibility limits cough propulsion.)

Eponyms are tropes, figurative literary devices useful in conveying a well-defined constellation of findings, e.g., the Pickwickian Syndrome(4). The nominal source is Samuel Pickwick esq., in Charles Dickens’s The Posthumous Papers of the Pickwick Club. The eponym actually refers to “Joe, ” “the fat boy,” who makes a brief appearance. I chose “Lady Windermere” because her British ethnicity, title, and name collectively conveyed fastidiousness, and her response, “How do you do, Lord Darlington. No, I can’t shake hands with you. My hands are all wet with the roses.” reinforced this image. That she fails the ostensive definition of the eponym—-lacking longevity, cough suppression, isolation of M. avium, and lingular shadowing(3)—-is hardly relevant: she is, after all, a fictional character. No comprehensive explanation for the distinctive peculiarities of LWS—-female exclusivity, isolation of M. avium absent preexistent pulmonary disease, and isolated middle lobe and lingular involvement—-other than that postulated, viz. a nidus of nonspecific chronic inflammation, initiated by cough suppression (“Ladies don’t spit.”—-attributed to Dame Margaret Turner-Warick), upon which M. avium engrafts(5). Because of the frequency of nonspecific inflammatory changes, surgeons exempt the lingula tip from biopsy undertaken to evaluate diffuse interstitial lung disease. Additional hypotheses, e.g., CF, violate Occam’s Razor (lex parsimoniae).

Minor points: 1) Failure to distinguish between “isolated bronchiectasis” and “bronchiectasis” constitutes a kind of cognitive entropy. 2) Among profoundly immunosuppressed individuals, M. avium presents as a systemic disease, typically a septicemic form, with pulmonary involvement, incidental. 3) With the exception of silicosis complicated by M. avium, in which, presumably, impaired alveolar macrophage function is the critical factor, persistent secretion pooling appears to be the unifying feature facilitating colonization and invasion by M. avium. It is characteristically seen in individuals with bronchiectasis, chronic bronchitis and cystic fibrosis, and it has been reported in persons with pulmonary alveolar proteinosis. I have encountered an instance in a chronically quadriparetic non-smoker with an ineffective cough and persistent upper lobe shadowing. 4) The author presumably intended “unknown etiology” for “unknown ideology.”(2)

References (1) Marchant JM, Chang AB. Evaluation and outcome of young children with chronic cough [letter]. Chest 2006; 130(4):1279-80 (2) Rubin BK. Did lady Windermere have cystic fibrosis? [editorial]. Chest 2006; 130(4) 937-38 (3) Reich JM, Johnson RE. Mycobacterium avium-intracellulare disease presenting as an isolated middle lobe or lingular pattern: Lady Windermere syndrome. Chest 1992; 101:1605-09 (4) Bickelmann AG, Burwell CS, Robin ED, Whaley RD. Extreme obesity associated with alveolar hypoventilation; a Pickwickian syndrome. Am J Med 1956; 21(5):811-18 (5) Dhillon SS, Watankunakom C. Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium infection due to voluntary cough suppression. Clin Infect Dis 2000; 30(3):572-75

editorials:
Decreased Recognition of the Post-Myocardial Infarction (Dressler) Syndrome in the Postinfarct Setting: Does It Masquerade as "Idiopathic Pericarditis" Following Silent Infarcts?
Spodick (1 November 2004) [Full text] [PDF]
Decreased Recognition of the Post-Myocardial Infarction (Dressler) Syndrome in the...
post mi pericarditis
23 December 2006
Previous eLetter Next eLetter Top
neil d kushner md
none

Send letter to journal:
Re: post mi pericarditis

vacation_doc{at}hotmail.com neil d kushner md

Why shouldn't a post mi pain , originating from inflammatory mediators, occur regardless of extent of the infarct? Could not the molecular reactions of inflammation be present throughout the surface of the pericardium andbe involved in effusion and instigate clinical pain? Your article is most excellent and thought provoking.

critical care reviews:
Adult Toxicology in Critical Care: Part I: General Approach to the Intoxicated Patient
Mokhlesi et al. (1 February 2003) [Abstract] [Full text] [PDF]
Adult Toxicology in Critical Care: Part I: General Approach to the Intoxicated Patient
Too early to draw a conclusion for activated charcoal
22 November 2006
Previous eLetter  Top
Yi Li,
emergency doctor
the emergency department, Peking Union Medical College Hospital, Beijing, China,
Xuezhong Yu

Send letter to journal:
Re: Too early to draw a conclusion for activated charcoal

billliyi{at}yahoo.com Yi Li, et al.

To the Editor:

We read with interest the study by Babak Mokhlesi et al (February 2003) (1) and we are puzzled by the statement that organophosphates cannot be absorbed by activated charcoal. The author does not state whether this conclusion was based on in vitro or in vivo studies. Furthermore this is not supported by a recent statement by the major clinical toxicology association (2)..

To determine if there are any relevant papers, we searched the PubMed database for ¡®charcoal and organophosphate¡¯ within the title/abstract area. A total of 25 papers were found of which 22 papers were about activated charcoal ingestion or hemoperfusion with a charcoal column. Of those 22 papers, 16 papers describe the routine use of charcoal therapy, 5 support (one for oral charcoal and 4 for hemoperfusion), and only 1 suggests that there is no benefit to the use of charcoal hemoperfusion. One paper investigates the absorptive capacity of activated charcoal in vitro at two different pH environments and over a wide range of charcoal:organophosphate ratios. The results show that large doses of activated charcoal (20:1) effectively bind dichloruos and parathion (about 85% and 60% respectively) under different pH conditions (3).

Hemoperfusion with a charcoal column may be useful in the extraction of organophosphates. The clearance values for hemoperfusion with coated activated charcoal were 83.70 ml/min for demeton-S-methyl sulfoxide, 59.20 ml/min for nitrostigmine and 87.84 ml/min for dimethoate. This suggests that activated charcoal can bind organophosphates in vivo (4). The one paper that opposes the use of hemoperfusion with charcoal does so not because of charcoal¡¯s inability to bind organophosphates, but rather because of the high binding of organophosphates to adipose tisse.

Reference: 1. Mokhlesi B, Leiken JB, Murray P, et al. General approach to the intoxicated patient: part 1. Chest 2003, 123:577-592. 2. American Academy of Clinical Toxicology and European Association of Poisons Centers and Clinical Toxicologists. Position Paper: Single-Dose Activated Charcoal. Clinical Toxicology 2005, 43:61¨C87. 3. Guven H, Tuncok Y, Gidener S, et al. In vitro absorption of dichlorvos and parathion by activated charcoal. J Toxicol Clin Toxicol 1994, 32:157- 63. 4. Okonek S. Probable progress in the therapy of organophosphate poisoning: extracorporeal hemodialysis and hemoperfusion. Arch Toxicol 1976,35:221-7. 5. Martinez CJ, Jurado M, Gimenez P, et al. Experience with hemoperfusion for organophosphate poisoning. Crit Care Med 1992, 20:1538-43.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American College of Chest Physicians.